导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.36% | 2585/4773 |
| 近一周 | -2.24% | 1570/5462 |
| 近一月 | -4.09% | 2210/5421 |
| 近一季 | -7.08% | 2286/5209 |
| 近半年 | -2.23% | 1831/4920 |
| 近一年 | 1.10% | 2400/4366 |
| 近两年 | 46.20% | 1601/2954 |
| 近三年 | 27.56% | 1160/2253 |
| 成立以来 | 38.02% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.65% 3334/4961 |
12.41% 2182/5312 |
- - |
- - |
| 2025 | 20.05% 2153/4813 |
-0.94% 2478/3635 |
2.29% 1677/4076 |
18.30% 2317/4524 |
0.15% 2182/4813 |
| 2024 | 16.40% 815/3463 |
2.52% 758/2808 |
-1.10% 929/3014 |
16.70% 1375/3129 |
-1.63% 1777/3463 |
| 2023 | -9.63% 1204/2656 |
4.02% 1067/2280 |
-3.90% 957/2385 |
-2.72% 728/2515 |
-7.07% 2042/2655 |
| 2022 | -18.61% 735/2207 |
-13.28% 723/1919 |
6.31% 726/2016 |
-13.20% 857/2113 |
1.71% 1171/2208 |
| 2021 | -1.58% 811/1822 |
-2.63% 681/1255 |
4.59% 867/1330 |
-4.99% 759/1466 |
1.70% 830/1822 |
| 2020 | 32.84% 473/1250 |
-8.75% 629/1028 |
13.03% 654/1067 |
14.04% 302/1164 |
12.95% 409/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国联安沪深300ETF联接A VS. 长安沪深300非周期A(740101) |